Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Income towards Parent Company: 2014-2025

Historic Income towards Parent Company for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -$14.2 million.

  • CytomX Therapeutics' Income towards Parent Company fell 348.06% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 102.59%. This contributed to the annual value of $31.9 million for FY2024, which is 5700.88% up from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Income towards Parent Company is -$14.2 million, which was down 9,139.61% from -$154,000 recorded in Q2 2025.
  • CytomX Therapeutics' Income towards Parent Company's 5-year high stood at $23.5 million during Q1 2025, with a 5-year trough of -$34.8 million in Q4 2021.
  • For the 3-year period, CytomX Therapeutics' Income towards Parent Company averaged around $3.7 million, with its median value being $837,000 (2023).
  • Within the past 5 years, the most significant YoY rise in CytomX Therapeutics' Income towards Parent Company was 2,155.20% (2024), while the steepest drop was 501.10% (2024).
  • CytomX Therapeutics' Income towards Parent Company (Quarterly) stood at -$34.8 million in 2021, then soared by 74.80% to -$8.8 million in 2022, then surged by 109.54% to $837,000 in 2023, then spiked by 2,155.20% to $18.9 million in 2024, then crashed by 348.06% to -$14.2 million in 2025.
  • Its Income towards Parent Company was -$14.2 million in Q3 2025, compared to -$154,000 in Q2 2025 and $23.5 million in Q1 2025.